SESSIONS

SESSION 1

Research in Nanomedicine in early stage of development – how to be prepared for translational research

From a point of view of technology developers generating their own technology on nanosystems, we will share the way they address the research & development on nanomedicine. Some examples will be presented and main challenges during this process will be discussed.

To be confirmed
11:30 - 11:50
Covadonga Paneda (Sylentis, Spain)
11:50 – 12:10
Valeria Grazu (University of Zaragoza, Spain)
12:10 - 12:30
Rene C.F. van Nostrum (Utrecht University, The Netherlands)
12:30 – 12:50
Damien Dupin (CIDETEC Nanomedicine, Spain)
12:50 – 13:20
SESSION 2

Microfluidics  technology  applied  to  nanoformulation

The advances on the use of microreactors for chemical production will be presented: principle behaviour of microfluidic systems, advantages of using microfluidics, scalability of the processes… On-line and in-line characterization for quality control that can be included in microfluidics systems will be discussed specially in the field of nanomanufacturing. Which are the similarities-differences, advantages-disadvantages, and challenges for nanomanufacturing comparing to small molecules manufacturing?.

Dr. Thomas R. Dietrich (IVAM, Germany)
15:00-15:20
Alice Kasjanow (MICRONIT, Germany)
15:20-15:40
Charlotte Wiles (CHEMTRIX, The Netherlands)
15:40-16:00
Graham Worrall (CPI, England)
16:00-16:20
SESSION 3

Advanced characterization techniques

From basic research to clinical development (validation, standardization of methods…), we will go through different approaches to fulfill characterization requirements (both physicochemical and biological) to advance in nanopharmaceuticlas’ development towards the market. An overview of new characterization techniques for nanomedicines will be showed, from the biggest challenges, to some achievements during the last years…. Some characterization techniques will be presented.

To be confirmed
17:00-17:20
Jose Crecente (University of Santiago de Compostela Spain)
17:20-17:40
Vicent J Nebot (Polypeptides, Spain)
17:40- 18:00
Vijaya Krihsna  (National University of Ireland, Galway)
18:00-18:20
SESSION 4

Nanomedicine and regulatory environment for nano-investigational medicinal products

During this session we will focus the attention on the regulatory science. We will go through the requirements in terms on regulatory in order to be able to enter Phase I clinical trial. Some European Regulatory Agencies-led initiatives, such as the European Innovation Network, for a better interaction between researchers and regulatory authorities will also be presented.

Mathieu Menta (UT2A, France)
9:00-9:20
Simon BACONNIER (EUNCL)
9:20-9:40
To be confirmed
9:40-10:00
Luigi Calzonai (Joint Research Center, ISPRA, Italy)
10:00-10:20
To be confirmed
10:20-10:40
SESSION 5

Pilot Plant

NanoPilot is one of the projects funded (under H2020) in this translational hub approach launched by the EC and promoted by the ETPN Nanomedine (www.nanopilot.eu). It final goal is to set-up a pilot plant that will be operating under GMP for the manufacturing of small batches of nanoformulated investigational medicinal products. Capacities of the new pilot plant will be presented, and a visit to the facilities could be organized based on the interest of attendees and depending on the activities going on during those days.

Maria Beatriz Silva (University of Lisbon, Portugal)
11:10-11:30
Francisco Arenal (MEJORAN, Spain)
11:30 - 11:50
Marcos Maroto (Instituto Fundación Teófilo Hernando IFTH, Spain)
11:50 – 12:10
César Hernández García (EU Innovation Network, AEMPS, Spain)
12:10-12:30